Artasensi A, Pedretti A, Vistoli G, Fumagalli L
3.1 SFN and fatty liver disease Fatty liver disease (FLD) is a common liver disease around the world with a broad spectrum from simple steatosis to steatohepatitis, fibrosis, and cirrhosis, and is characterized by excessive lipid accumulation in the liver (Louvet and Mathurin, 2015
(Dependent on patient's needs) Dose: 250 g (also known as micrograms(mcg))in cats and 250 2000 g (also known as micrograms (mcg))in dogs, depending on the size of the patient: For parenteral cobalamin supplementation: Protocol: weekly injections for 6 weeks, then one dose a month later, and retesting one month after the last dose( dependent on patient's needs) For either oral or parenteral supplementation, if the underlying disease process has resolved and cobalamin body stores have been replenished, serum cobalamin concentration should be supranormal at the time of reevaluation
Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs
Treatment involves dietary optimisation, oral supplementation for mild deficiency, or intramuscular hydroxocobalamin injections for significant deficiency or neurological involvement
Results may vary depending on individual metabolism and the intended use
